Microdose administration of ABY-029, an anti-epidermal growth factor receptor Affibody molecule conjugated to IRDye 800CW, is being studied in a Phase 0 trial for resection of soft-tissue sarcomas. The excised tissue of a single patient in the microdose administration group was imaged with both a wide-field fluorescence surgical system and a flatbed scanning fluorescence imaging system. Here the resultant fluorescence from a breadloaf section of the primary tumor specimen and six region-specific tissue samples collected from that breadloaf are compared using these two imaging systems -a flatbed, black-box, fluorescence scanning system, the Odyssey CLx, and a open-air, wide-field, preclinical surgical imaging system, the Solaris. Florescence signal is compared using a variety of methods including: mean, standard deviation, variance, tumor-to-background ratio, biological-variance ratio, and contrast-to-noise ratio. The images produced from the Odyssey scanner have higher signal variance but more accurately represent the EGFR expression in small tissue sections. The Solaris system has higher depth sensitivity and volume averaging, and as such has lower signal variation and higher contrast-to-noise ratio.
INTRODUCTION
Fluorescence-guided surgery (FGS) is a developing imaging approach that aims to improve the safety and efficacy of surgery by maximizing the tumor tissue excised from patient tissue, and minimizing damage to essential physiological structures. Molecular targeted FGS utilizes targeted fluorescent reporters that bind to specific proteins within tissues of interest, with higher binding capabilities tumors as compared to normal tissues due to overexpression of key proteins. Recently, we have been motivated to investigate FGS using the US Food and Drug Administration (FDA) exploratory Investigative New Drug (eIND) pathway that emphasizes microdose studies (Phase 0) prior to pursuing more expensive Phase 1 trials [1] . The eIND pathway is additionally appealing because production, safety testing, and Phase 0 trials of fluorescent protein molecules is feasible with a single National Institute of Health (NIH) grant [2] .
Previous studies have pioneered the clinical implementation of FGS using therapeutic epidermal growth factor receptor (EGFR)-targeting antibodies labeled with near-infrared dyes, such as IRDye ® 800CW (LI-COR Biosciences, Inc.). The trailblazing Phase I safety and dose escalation study of cetuximab-IRDye800CW for human FGS demonstrated tumor-to-background ratios (TBR) in the range of 4-5X with sub-therapeutic doses, 2-5 days postadministration [3] . However, microdose administration (1% therapeutic dose) of these antibody agents did not yield significant TBRs in vivo, and adverse events typical of anti-EGFR therapy were experienced by patients at the higher * kimberley. 
MATERIALS AND METHODS

ABY-029
ABY-029 was manufactured under Good Manufacturing Practices (GMP) conditions at the University of Alabama Birmingham Vector Production Facility as previously described [16] . ABY-029 was by packaged in single microdose aliquots -defined by the FDA as 30 nanomoles (237 μg) -in an amber vial dissolved in 5 mL of sterile saline. ABY-029 was used under an eIND 122681 for allowance of experimental human studies.
Patient Enrollment
The soft-tissue sarcoma, ABY-029 Phase 0 study (NTC03154411) protocol was approved by the Dartmouth College Center for Protection of Human Subjects (CPHS) Institutional Review Board (IRB). The subject participated under informed consent by signing a HIPAA-compliant form to document this understanding. The patient was enrolled by meeting the following criteria: tumor judged to be suitable for open surgical resection based on preoperative imaging studies, subject ≥18 years of age, and valid consent signed by subject. Patients were excluded from the study if they were on any anti-EGFR therapies, either investigational or FDA approved, or were female and pregnant, or breastfeeding. The patient had a preoperative histological diagnosis of primary soft-tissue sarcoma. Standard H&E and epidermal growth factor receptor (EGFR) immunohistochemistry (IHC) were performed on diagnostic tumor biopsy samples. EGFR IHC was scored by a clinical pathologist (author KL) based on a previously determined scale of 0-3+ [17] , where 0 = no staining; 1+ = partial membranous staining around cells; 2+ = weak membranous staining completely around cells; and 3+ = strong membranous staining completely around cells. A zero (0) score was considered EGFR negative, and scores from 1+ to 3+ were classified as EGFR positive (EGFR+).
Soft-tissue sarcoma study data
On the day of surgery, the patient was administered a microdose of ABY-029 (30 nanomoles, 237 μg) by 5 mL intravenous bolus, 1-3 hours prior to surgery. Sarcomas were removed as a single specimen by wide local excision and transferred to clinical pathology where the tissue was inked and breadloafed into ~ 2.5 cm sections. One representative slice was selected and scanned for fluorescence in the 800 nm channel on an Odyssey CLx (LI-COR Biosciences, Inc., Lincoln, NE) at low resolution (337-μm) and then imaged using the 750 nm channel (735nm excitation, 770-809 nm emission collection) of the Solaris (Perkin Elmer, XXX, MA). Six ~1-cm 2 regions -three high-fluorescence and three low fluorescence locations -were selected from the slice and rescanned at higher resolution (42-μm) on the Odyssey and again on the Solaris. All fluorescent images were collected with calibration paper in the field-of-view. These small tissue sections were blocked, fixed and stained for pathology.
Pathology
Routine H&E staining and EGFR IHC was performed on the six ROI tissue specimens by Pathology Translation Research Services at Dartmouth-Hitchcock. EGFR IHC staining was completed as described previously [17] . Sections of placenta were used as positive controls, and surgical tissue stained only with the secondary antibody was used as a negative control. EGFR IHC stained tissue was assigned a score from 0-3+ by clinical pathologist (author KL).
Ex vivo fluorescent image analysis
ABY-029 fluorescent images from the Odyssey and Solaris were individually background subtracted and then normalized to the maximum signal generated from Odyssey CLx test paper, provided by the manufacturer, prior to fluorescence intensity determination.
Breadloaf Section of Primary Sample
For the primary sarcoma breadloaf specimen, the mean, standard deviation (st dev) and variance were calculated for the whole specimen, tumor region, normal tissue (fat and muscle), fat, and muscle. The tumor-tobackground ratio (TBR), biological-variance ratio (BVR), and contrast to noise ratio (CNR) were calculated by using equations 1-3, respectively:
where I(FL) represents the mean fluorescent intensity, and SD(FL) is the standard deviation of the fluorescent intensities in the tumor (TUM) or normal tissues (NORM).
Region-of-Interest Sections of Primary Breadloaf Sample
For each of the tumor ROI sections, the average fluorescence intensities from the Odyssey and Solaris were determined and plotted against the average intensity of the corresponding IHC stain, assessed with the H DAB Color Deconvolution add-on in FIJI (FIJI is Just Image J, LOCI, Madison, WI) [18, 19] . Fluorescence intensity was plotted against IHC stain intensity and fit with a linear regression using Pearson's correlation.
RESULTS AND DISCUSSION
The enrolled patient had a diagnosis of undifferentiated pleomorphic sarcoma, with a 2/3+ EGFR IHC score on the preliminary diagnostic biopsy. The sarcoma was extracted 4.12 hours after administration of ABY-029, and the specimen was sent directly to pathology for processing. The breadloaf section of the primary specimen chosen for imaging is shown in Figure 1 , with regions of tumor, fat, and muscle indicated. Note that for analysis, 'whole specimen' is tumor, fat, and muscle together, while 'normal tissue' is a considered a combination of fat and muscle. ABY-029 fluorescence resulting from microdose administration is clearly observed in both the Odyssey CLx and Solaris imaging systems ( Figure 2 ). Table 1 reports the typically calculated parameters of fluorescence intensity in a variety of regions-of-interest, including the mean signal, standard deviation, and the variance. The mean calibrated fluorescence intensity and the standard deviation of the intensity of the Whole Specimen are on the same order of magnitude for the Solaris and Odyssey systems. However, when looking at the Tumor region alone, while the mean fluorescence intensities between to two systems are on the same order of magnitude, in the Odyssey images the standard deviation is an order of magnitude higher and the variance is two orders of magnitude higher than in the Solaris images. The normal tissues, and fat and muscle considered alone, again only differ considerably in the variance. It is interesting to note that the tumor and normal tissues have similar variance when imaged in the Solaris system, but the tumor tissue displays much higher variance (~2 orders of magnitude) as compared to the normal tissues when imaged with the Odyssey scanner.
The most often reported value in clinical and pre-clinical fluorescence-guided surgery is the tumor-tobackground, or the tumor-to-normal tissue, ratio (TBR or TNR). However, there is current debate whether TBR is the best value to report during fluorescence guided surgery, because it does not take into consideration the variance of the signal, has been shown not in increase with increasing fluorophore dose, and is dependent on the dynamic range of the instruments [20] . In Table 2 , the TBR values of tumor-to-normal tissue are summarized in addition to the biologicalvariability ratio (BVR) and the contrast-to-noise ratio (CNR). The Odyssey scanning system provides a higher TBR than the Solaris between the tumor and normal surrounding tissues. BVR is the biological equivalent to the signal-to-noise ratio (SNR) that is often calculated for imaging systems using instrument noise as the background. Here, the Odyssey fluorescence signal in the tumor is 5.7 times higher than the 'noise' or the signal in the normal tissue. The Solaris only displays a BVR of 3.6, indicating that the Odyssey is better at detecting differences in the tissue types. The CNR is a measure that determines overall image quality. Here, we show that the Odyssey has a lower CNR than the Solaris for the same tissue sample (0.8 and 1.1, respectively) indicating that even though the mean fluorescence signal is high in the tumor, the overall noise in the image is also high making it more difficult to distinguish true signal [20, 21] . Six specific regions of interest ( Figure 4) were isolated from the primary specimen breadloaf and imaged separately on the Solaris and the Odyssey at high resolution. The regions were selected so that 3 contained highfluorescing regions and 3 contained moderate-to-low fluorescence regions in order to maximize the variations in EGFR expression. Necrotic regions were avoided as they were very low in fluorescence intensity and anticipated to be devoid of EGFR based on pre-clinical experience (data not shown). After imaging, these sections were formalin fix and stained for H&E and EGFR IHC. All the ROI sections were assigned an EGFR score of 3+, with the exception of ROI 5 that was assigned a score of 2+. It is clearly visible in Figure 4 that the ABY-029 fluorescence is spatially similar to the EGFR IHC staining patterns, especially in the case of the Odyssey. The Solaris images in general follow similar spatial patterning to the EGFR IHC but are more blurred in nature. The fluorescence intensity from each tumor section was analyzed for both the Odyssey and the Solaris systems and plotted against the EGFR IHC stain intensity, isolated from the brown coloring in the images ( Figure 5) . Interestingly, the fluorescence intensity of ABY-029 is moderately, positively correlated to the EGFR IHC stain intensity (r = 0.48) using Pearson's correlation. However, the fluorescence intensity measured from the Solaris images is moderately, negatively correlated to the EGFR IHC stain intensity (r = -0.34). These results should be taken lightly as they only represent one patient sample but it does indicate that the Odyssey fluorescence intensity most closely matches the EGFR expression. The correlation could be further improved by weighting the intensities by area fraction of EGFR expression, or only analyzing regions that are EGFR positive. 
